在喘小鼠中,抗S100A4抗体的使用缓解了支气管上皮质-介质细胞过渡
Shuang Liu1, Min Liu1, Jinnan Zhong1
1Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jianghan University, Wuhan 430000, Hubei, China.
Open medicine (Warsaw, Poland)
|October 24, 2023
概括
蛋白质S100A4通过促进呼吸道炎症和上皮-介质细胞过渡 (EMT) 来促进喘. 在小鼠模型中,用抗体阻止S100A4可降低喘症状,并预防EMT.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 喘是一种慢性呼吸道疾病,其特点是气道炎症和重塑.
- 表皮介质转换 (EMT) 在喘期间在呼吸道重塑中发挥着重要作用.
- 蛋白质S100A4已涉及到各种炎症和纤维化的过程.
研究的目的:
- 调查S100A4在喘发病过程中的作用,特别是其对呼吸道炎症和EMT的影响.
- 在喘小鼠模型中评估针对S100A4的治疗潜力.
主要方法:
- 在小鼠中使用卵蛋白 (OVA) 敏感化和挑战诱导喘.
- 小鼠接受了抗S100A4抗体或控制IgG的治疗.
- 评估了气道炎症,气道过敏反应和气道改造.
- 通过西式涂抹分析分析了EMT标记物 (维门丁,α-SMA,E-cadherin).
- 在用家用粉尘 (HDM) 刺激的人类支气管上皮细胞中评估了EMT,并用S100A4降低调节治疗.
主要成果:
- 在喘小鼠中,S100A4水平升高.
- 抗S100A4抗体治疗减弱了呼吸道的过敏反应,炎症和重塑.
- 在S100A4抑制下调的EMT标志物 (vimentin,α-SMA) 和上调的E-cadherin.
- 在HDM刺激的人类支气管上皮细胞中降低S100A4抑制EMT.
结论:
- S100A4促进呼吸道炎症和喘中的EMT.
- 用抗体向S100A4是一种潜在的喘治疗策略.
- 抑制S100A4可以通过防止EMT来改善气道重塑.
相关概念视频
01:20Asthma: Pathogenesis and Management
421
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
421
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324